Product category:
Reagents and catalysts
News Release from: Invitrogen | Subject: Lipofectamine LTX
Edited by the Laboratorytalk Editorial
Team on 05 September 2006
The next generation of transfection
reagents
Lipofectamine LTX provides highly effective delivery of DNA into a wide range of cell types and a significantly lower toxicity profile
Invitrogen has introduced a key new product into its successful line of transfection reagents Lipofectamine LTX, carrying on the tradition of one of the company's best-selling technologies - Lipofectamine 2000 - provides highly effective delivery of DNA into a wide range of cell types and a significantly lower toxicity profile
This article was originally published on Laboratorytalk on 14 Sep 2005 at 8.00am (UK)
Related stories
Profiling service for immune response biomarkers
Provides researchers with a discovery method for rapid identification of biomarkers specific to disease states that result from altered immunoreactivity to self proteins
Cell lines keep on growing
Rapidly and reliably determine the intracellular status of key signal transduction pathways upon exposure to drug candidates or other stimuli
Lipofectamine LTX Reagent effectively delivers DNA into the cell, the first critical step in characterizing gene function, and demonstrates high levels of transfection efficiency and protein expression with more than 90 percent viability for a wide range of cells, including primary neuronal cells and other disease-relevant cell types.
Understanding gene function, in turn, helps researchers learn about the molecular basis of disease formation and develop potential therapeutic strategies to combat disease.
The introduction of Lipofectamine LTX complements Invitrogen's release earlier this year of another member of the Lipofectamine product line.
Lipofectamine RNAi MAX is a RNAi-specific transfection reagent that offers high transfection efficiency and low toxicity profiles on a wide variety of cell types for siRNA gene knockdown experiments.
"These technologies add significant capabilities to a transfection portfolio that is already widely adopted throughout the industry and was instrumental in establishing applications such as RNAi and stem cell research," said Claude Benchimol, senior vice president of research and development for Invitrogen.
"Our commitment to continual improvement in our core technologies is demonstrated in the release of Lipofectamine LTX and Lipofectamine RNAi MAX," concluded Mark Gardner, Invitrogen's vice president of molecular biology essentials.
"Lipofectamine 2000 is one of our company's top products, and with the advances these new reagents provide, we have a chance to support new and rapidly expanding research applications with the next generation of gene delivery solutions.".
• Invitrogen: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
